Skip to main content
Erschienen in: Tumor Biology 2/2014

01.02.2014 | Research Article

Association of CYP3A4, CYP3A5 polymorphisms with lung cancer risk in Bangladeshi population

verfasst von: Mohammad Safiqul Islam, A. G. M. Mostofa, Maizbha Uddin Ahmed, Muhammad Shahdaat Bin Sayeed, Md. Rajib Hassan, Abul Hasnat

Erschienen in: Tumor Biology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

The rate of direct smoking, second hand smoking, and smokeless tobacco users as well as the amount of environmental pollutant like polycyclic aromatic hydrocarons is increasing in Bangladesh. Therefore, the prevalence of lung cancer is increasing day by day. To the best of our knowledge, no pharmacogentic study of CYP3A4, CYP3A5 genes has been reported on Bangladeshi population relating those with lung cancer. The present study was conducted to determine the association of CYP3A4, CYP3A5 gene polymorphisms and tobacco smoking in the development of lung cancer in Bangladeshi population. A case–control study was carried out on 106 lung cancer patients and 116 controls to investigate three allelic variants—CYP3A4*1B, CYP3A5*3, and CYP3A5*6 using Polymerase Chain Reaction Restriction Fragment Length Polymorphism. Risk of lung cancer was estimated as odds ratio (OR) and 95 % confidence interval (CI) using unconditional logistic regression models. The variant allele frequencies for CYP3A4*1B (*1A/*1B + *1B/*1B) were 2.83 % and 0.86 % and that of CYP3A5*3 (*1A/*3 + *3/*3) were 88.68 % and 85.34 % in cases and controls, respectively. Individual carrying at least one variant allele of CYP3A4*1B (CYP3A4*1A/1B + *1B/1B) has a 3.35 times more risk (OR = 3.35, 95 % Cl = 0.34-32.71, p = 0.271) for developing lung cancer whereas individual carrying at least one variant allele of CYP3A5 (CYP3A5*1A/3 + *3/3) has a 1.26 times more risk (OR = 1.35, 95 % Cl = 0.61–2.97) and both are statistically non-significant (p > 0.05). CYP3A5*6 was absent in the study population. No association of lung cancer with the mentioned polymorphisms was found both in heavy and light smokers. In the cases of all three major types of lung cancer—squamous cell carcinoma, adenocarcinoma, and small cell carcinoma—significantly strong relationships (p ˂ 0.05) have been found. To confirm the association of lung cancer with the mentioned polymorphisms, large number volunteers (patients and controls) will be required.
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRef
2.
Zurück zum Zitat Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr; last accessed: July. 1, 2013. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://​globocan.​iarc.​fr; last accessed: July. 1, 2013.
3.
Zurück zum Zitat Haque AFMR. Prevention and control of noncommunicable diseases: The Bangladesh perspective. Commonwealth Health Ministers’ Update 2011. Melton, Woodbridge, Suffolk: Pro-Brook Publishing Limited; 2011. p. 100–1. Haque AFMR. Prevention and control of noncommunicable diseases: The Bangladesh perspective. Commonwealth Health Ministers’ Update 2011. Melton, Woodbridge, Suffolk: Pro-Brook Publishing Limited; 2011. p. 100–1.
5.
Zurück zum Zitat Lung Carcinoma: Tumors of the Lungs. Merck Manual Professional Edition, Online edition. Retrieved July.1, 2013. Lung Carcinoma: Tumors of the Lungs. Merck Manual Professional Edition, Online edition. Retrieved July.1, 2013.
6.
Zurück zum Zitat Horn L, Pao W, Johnson DH. Harrison’s Principles of Internal Medicine. 18th ed. McGraw-Hill; 2012. Horn L, Pao W, Johnson DH. Harrison’s Principles of Internal Medicine. 18th ed. McGraw-Hill; 2012.
7.
Zurück zum Zitat Rahman MH, Arslan MI, Chen Y, Ali S, Parvin T, Wang LW, et al. Polycyclic aromatic hydrocarbon-DNA adducts among rickshaw drivers in Dhaka City Bangladesh. Int Arch Occup Environ Health. 2003;76(7):533–8.PubMedCrossRef Rahman MH, Arslan MI, Chen Y, Ali S, Parvin T, Wang LW, et al. Polycyclic aromatic hydrocarbon-DNA adducts among rickshaw drivers in Dhaka City Bangladesh. Int Arch Occup Environ Health. 2003;76(7):533–8.PubMedCrossRef
11.
Zurück zum Zitat U.S. Department of Health and Human Services. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2010. U.S. Department of Health and Human Services. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2010.
12.
Zurück zum Zitat Sobti RC, Sharma S, Joshi A, Jindal SK, Janmeja A. Genetic polymorphism of the CYP1A1, CYP2E1, GSTM1 and GSTT1 genes and lung cancer susceptibility in a north indian population. Mol Cell Biochem. 2004;266(1–2):1–9.PubMedCrossRef Sobti RC, Sharma S, Joshi A, Jindal SK, Janmeja A. Genetic polymorphism of the CYP1A1, CYP2E1, GSTM1 and GSTT1 genes and lung cancer susceptibility in a north indian population. Mol Cell Biochem. 2004;266(1–2):1–9.PubMedCrossRef
13.
Zurück zum Zitat Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006;25(11):1679–91.PubMedCrossRef Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006;25(11):1679–91.PubMedCrossRef
14.
Zurück zum Zitat Coto E, Tavira B, Marín R, Ortega F, López-Larrea C, Ruiz-Ortega M, et al. Functional polymorphisms in the CYP3A4, CYP3A5, and CYP21A2 genes in the risk for hypertension in pregnancy. Biochem Biophys Res Commun. 2010;397(3):576–9.PubMedCrossRef Coto E, Tavira B, Marín R, Ortega F, López-Larrea C, Ruiz-Ortega M, et al. Functional polymorphisms in the CYP3A4, CYP3A5, and CYP21A2 genes in the risk for hypertension in pregnancy. Biochem Biophys Res Commun. 2010;397(3):576–9.PubMedCrossRef
15.
Zurück zum Zitat Piipari R, Savela K, Nurminen T, Hukkanen J, Raunio H, Hakkola J, et al. Expression of CYP1A1, CYP1B1 and CYP3A, and polycyclic aromatic hydrocarbon-DNA adduct formation in bronchoalveolar macrophages of smokers and non-smokers. Int J Cancer. 2000;86:610–6.PubMedCrossRef Piipari R, Savela K, Nurminen T, Hukkanen J, Raunio H, Hakkola J, et al. Expression of CYP1A1, CYP1B1 and CYP3A, and polycyclic aromatic hydrocarbon-DNA adduct formation in bronchoalveolar macrophages of smokers and non-smokers. Int J Cancer. 2000;86:610–6.PubMedCrossRef
16.
Zurück zum Zitat Dally H, Edler L, Jäger B, Schmezer P, Spiegelhalder B, Dienemann H, et al. The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics. 2003;13(10):607–18.PubMedCrossRef Dally H, Edler L, Jäger B, Schmezer P, Spiegelhalder B, Dienemann H, et al. The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics. 2003;13(10):607–18.PubMedCrossRef
17.
Zurück zum Zitat El Sankary W, Gibson GG, Ayrton A, Plant N. Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab Dispos. 2001;29:1499–504.PubMed El Sankary W, Gibson GG, Ayrton A, Plant N. Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab Dispos. 2001;29:1499–504.PubMed
18.
Zurück zum Zitat Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002;54:1271–94.PubMedCrossRef Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002;54:1271–94.PubMedCrossRef
19.
Zurück zum Zitat Zhou Q, Yu X, Shu C, Cai Y, Gong W, Wang X, et al. Analysis of CYP3A4 genetic polymorphisms in Han Chinese. J Hum Genet. 2011;56(6):415–22.PubMedCrossRef Zhou Q, Yu X, Shu C, Cai Y, Gong W, Wang X, et al. Analysis of CYP3A4 genetic polymorphisms in Han Chinese. J Hum Genet. 2011;56(6):415–22.PubMedCrossRef
21.
Zurück zum Zitat Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383–91.PubMedCrossRef Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383–91.PubMedCrossRef
22.
Zurück zum Zitat Balram C, Zhou Q, Cheung YB, Lee EJ. CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations. Eur J Clin Pharmacol. 2003;59(2):123–6.PubMed Balram C, Zhou Q, Cheung YB, Lee EJ. CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations. Eur J Clin Pharmacol. 2003;59(2):123–6.PubMed
23.
Zurück zum Zitat Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst. 1998;90(16):1225–9.PubMedCrossRef Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst. 1998;90(16):1225–9.PubMedCrossRef
24.
Zurück zum Zitat Paris PL, Kupelian PA, Hall JM, Williams TL, Levin H, Klein EA, et al. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev. 1999;8:901–5.PubMed Paris PL, Kupelian PA, Hall JM, Williams TL, Levin H, Klein EA, et al. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev. 1999;8:901–5.PubMed
25.
Zurück zum Zitat Spurdle AB, Goodwin B, Hodgson E, Hopper JL, Chen X, Purdie DM, et al. The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics. 2002;12:355–66.PubMedCrossRef Spurdle AB, Goodwin B, Hodgson E, Hopper JL, Chen X, Purdie DM, et al. The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics. 2002;12:355–66.PubMedCrossRef
26.
Zurück zum Zitat Tayeb MT, Clark C, Haites NE, Sharp L, Murray GI, McLeod HL. CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. Br J Cancer. 2003;88:928–32.PubMedCentralPubMedCrossRef Tayeb MT, Clark C, Haites NE, Sharp L, Murray GI, McLeod HL. CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. Br J Cancer. 2003;88:928–32.PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Tayeb MT, Clark C, Sharp L, Haites NE, Rooney PH, Murray GI, et al. CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncol Rep. 2002;9:653–5.PubMed Tayeb MT, Clark C, Sharp L, Haites NE, Rooney PH, Murray GI, et al. CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncol Rep. 2002;9:653–5.PubMed
28.
Zurück zum Zitat Dandara C, Ballo R, Parker MI. CYP3A5 genotypes and risk of oesophageal cancer in two South African populations. Cancer Lett. 2005;225:275–82.PubMedCrossRef Dandara C, Ballo R, Parker MI. CYP3A5 genotypes and risk of oesophageal cancer in two South African populations. Cancer Lett. 2005;225:275–82.PubMedCrossRef
29.
Zurück zum Zitat Nogal A, Coelho A, Araújo I, Azevedo A, Faria M, Soares R, et al. CYP3A5*3 genotypes and advanced non-small cell lung cancer development. J Clin Oncol. 2007;25(18S):21030. Nogal A, Coelho A, Araújo I, Azevedo A, Faria M, Soares R, et al. CYP3A5*3 genotypes and advanced non-small cell lung cancer development. J Clin Oncol. 2007;25(18S):21030.
30.
Zurück zum Zitat Islam MS, Ahmed MU, Bin Sayeed MS, Maruf AA, Mostofa AGM, Syed MAH, et al. Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population. Clin Chim Acta. 2013;416:11–9.PubMedCrossRef Islam MS, Ahmed MU, Bin Sayeed MS, Maruf AA, Mostofa AGM, Syed MAH, et al. Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population. Clin Chim Acta. 2013;416:11–9.PubMedCrossRef
31.
Zurück zum Zitat Maruf AA, Ahmed MU, Yasmin H, Ullah MA, Azad MA, Daly AK, et al. Genotypes and phenotypes of CYP3A in Bangladeshi population. Clin Chim Acta. 2011;412(7–8):531–6.PubMedCrossRef Maruf AA, Ahmed MU, Yasmin H, Ullah MA, Azad MA, Daly AK, et al. Genotypes and phenotypes of CYP3A in Bangladeshi population. Clin Chim Acta. 2011;412(7–8):531–6.PubMedCrossRef
32.
Zurück zum Zitat Fukuen S, Fukuda T, Maune H, Ikenaga Y, Yamamoto I, Inaba T, et al. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6 in a Japanese population. Pharmacogenetics. 2002;12:331–4.PubMedCrossRef Fukuen S, Fukuda T, Maune H, Ikenaga Y, Yamamoto I, Inaba T, et al. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6 in a Japanese population. Pharmacogenetics. 2002;12:331–4.PubMedCrossRef
33.
Zurück zum Zitat Wang JJ, Zheng Y, Sun L, Wang L, Yu PB, Li HL, et al. CYP1A1 Ile462Val polymorphism and susceptibility to lung cancer: a meta-analysis based on 32 studies. Eur J Cancer Prev. 2011;20(6):445–52.PubMedCrossRef Wang JJ, Zheng Y, Sun L, Wang L, Yu PB, Li HL, et al. CYP1A1 Ile462Val polymorphism and susceptibility to lung cancer: a meta-analysis based on 32 studies. Eur J Cancer Prev. 2011;20(6):445–52.PubMedCrossRef
34.
Zurück zum Zitat McKay JD, Hashibe M, Hung RJ, Wakefield J, Gaborieau V, Szeszenia-Dabrowska N, et al. Sequence variants of NAT1 and NAT2 and other xenometabolic genes and risk of lung and aerodigestive tract cancers in Central Europe. Cancer Epidemiol Biomarkers Prev. 2008;17(1):141–7.PubMedCrossRef McKay JD, Hashibe M, Hung RJ, Wakefield J, Gaborieau V, Szeszenia-Dabrowska N, et al. Sequence variants of NAT1 and NAT2 and other xenometabolic genes and risk of lung and aerodigestive tract cancers in Central Europe. Cancer Epidemiol Biomarkers Prev. 2008;17(1):141–7.PubMedCrossRef
35.
Zurück zum Zitat Sobti RC, Kaur P, Kaur S, Janmeja AK, Jindal SK, Kishan J, et al. Combined effect of GSTM1, GSTT1 and GSTP1 polymorphisms on histological subtypes of lung cancer. Biomarkers. 2008;13(3):282–95.PubMedCrossRef Sobti RC, Kaur P, Kaur S, Janmeja AK, Jindal SK, Kishan J, et al. Combined effect of GSTM1, GSTT1 and GSTP1 polymorphisms on histological subtypes of lung cancer. Biomarkers. 2008;13(3):282–95.PubMedCrossRef
36.
Zurück zum Zitat Sobti RC, Sharma S, Joshi A, Jindal SK, Janmeja A. CYP1A1 and CYP2D6 polymorphism and risk of lung cancer in a North Indian population. Biomarkers. 2003;8(5):415–28.PubMedCrossRef Sobti RC, Sharma S, Joshi A, Jindal SK, Janmeja A. CYP1A1 and CYP2D6 polymorphism and risk of lung cancer in a North Indian population. Biomarkers. 2003;8(5):415–28.PubMedCrossRef
37.
Zurück zum Zitat Timofeeva MN, Kropp S, Sauter W, Beckmann L, Rosenberger A, Illig T, et al. CYP450 polymorphisms as risk factors for early-onset lung cancer: gender-specific differences. Carcinogenesis. 2009;30(7):1161–9.PubMedCrossRef Timofeeva MN, Kropp S, Sauter W, Beckmann L, Rosenberger A, Illig T, et al. CYP450 polymorphisms as risk factors for early-onset lung cancer: gender-specific differences. Carcinogenesis. 2009;30(7):1161–9.PubMedCrossRef
38.
Zurück zum Zitat Sailaja K, Rao DN, Rao DR, Vishnupriya S. Analysis of CYP3A5*3 and CYP3A5*6 gene polymorphisms in Indian chronic myeloid leukemia patients. Asian Pac J Cancer Prev. 2010;11(3):781–4.PubMed Sailaja K, Rao DN, Rao DR, Vishnupriya S. Analysis of CYP3A5*3 and CYP3A5*6 gene polymorphisms in Indian chronic myeloid leukemia patients. Asian Pac J Cancer Prev. 2010;11(3):781–4.PubMed
39.
Zurück zum Zitat Van Schaik RH. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest New Drugs. 2005;23(6):513–22.PubMedCrossRef Van Schaik RH. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest New Drugs. 2005;23(6):513–22.PubMedCrossRef
40.
Zurück zum Zitat Maruf AA, Ahmed MU, Azad MA, Ahmed M, Hasnat A. CYP3A genotypes in Bangladeshi tuberculosis patients. Bangladesh Med Res Counc Bull. 2012;38(1):1–5.PubMedCrossRef Maruf AA, Ahmed MU, Azad MA, Ahmed M, Hasnat A. CYP3A genotypes in Bangladeshi tuberculosis patients. Bangladesh Med Res Counc Bull. 2012;38(1):1–5.PubMedCrossRef
41.
Zurück zum Zitat Azarpira N, Ashraf MJ, Khademi B, Darai M, Hakimzadeh A, Abedi E. Study the polymorphism of CYP3A5 and CYP3A4 loci in Iranian population with laryngeal squamous cell carcinoma. Mol Biol Rep. 2011;38(8):5443–8.PubMedCrossRef Azarpira N, Ashraf MJ, Khademi B, Darai M, Hakimzadeh A, Abedi E. Study the polymorphism of CYP3A5 and CYP3A4 loci in Iranian population with laryngeal squamous cell carcinoma. Mol Biol Rep. 2011;38(8):5443–8.PubMedCrossRef
Metadaten
Titel
Association of CYP3A4, CYP3A5 polymorphisms with lung cancer risk in Bangladeshi population
verfasst von
Mohammad Safiqul Islam
A. G. M. Mostofa
Maizbha Uddin Ahmed
Muhammad Shahdaat Bin Sayeed
Md. Rajib Hassan
Abul Hasnat
Publikationsdatum
01.02.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 2/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1230-0

Weitere Artikel der Ausgabe 2/2014

Tumor Biology 2/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.